Intratracheal injection of manganese superoxide dismutaseplasmid/liposome (MnSOD-PL) complexes has been demonstrated to delay the onset and reduce the extent of ionizing irradiation-induced murine pulmonary organizing alveolitis/ fibrosis. To facilitate translation of this modality to clinical fractionated radiotherapy, inhalation delivery of MnSOD-PL was developed using an ultrasonic nebulizer. Transgene product was quantitated by immunohistochemical quantitation and pulmonary tissue levels of MnSOD biochemical activity. C57BL/6NHsd female mice demonstrated a plasmid dose-dependent increased expression of MnSOD transgene product over the range of 250 mg-2.5 mg of MnSOD-PL administered over a constant 5 min interval. Delivery of a constant concentration of 500 mg of MnSOD-PL with varying times of administration ranging from 0.5 to 10 min demonstrated optimal MnSOD expression at 5 min. Mice pretreated by inhalation delivery of MnSOD-PL demonstrated significantly improved survival after 20 Gy single fraction irradiation to both lungs compared to LacZ-PL inhalation-treated or irradiated control mice. Mice receiving 10 fractions of 3.5 cGy demonstrated increased pulmonary MnSOD transgene product activity by a protocol of every Monday-Wednesday or daily inhalation of MnSOD-PL. Thus, inhalation radioprotective gene therapy using MnSOD-PL provides a practical and effective method for delivery of lung-specific radioprotection during fractionated radiotherapy protocols in a mouse model. Gene Therapy (2005) 12, 685-693.
Introduction
Pulmonary damage remains a major dose-limiting toxicity in clinical radiotherapy of lung and esophagus cancer. [1] [2] [3] [4] [5] [6] Acute radiation pneumonitis, subacute pulmonary diffusion defects, and late radiation fibrosis remain significant complications to the development of more effective radiation treatments. 5, 6 Studies of lung toxicity have documented the importance of ionizing radiation dose fraction size, total dose, time course of delivery of fractionated radiotherapy, and the significant factor of volume of lung irradiated. 3, 5, 6 Modern techniques of multifield conformal radiotherapy 1,2 and intensity modulated radiotherapy (IMRT) 7 have facilitated precise delivery of the high dose to tumor volumes that are now precisely defined by CT, MRI, and PET scanning; 7 however, these new modalities also deliver significant doses to normal tissues in the transit volume, which is the normal tissue through which the irradiation passes during irradiation of the tumor, predominantly normal lung. 2, 3, 5, 6 Chemotherapy drugs including Taxol, Carboplatinum, and Gemcitabine used for both primary tumor radiosensitization and to treat microscopic metastatic disease also sensitize normal lung to radiation damage. 2, 8 Since most lung and all esophageal cancers are central mediastinal in anatomic location, transit volumes involving both lungs are common in radiotherapy treatment plans. [1] [2] [3] [9] [10] [11] Dose escalation protocols to attempt to derive local control in over 30% of patients with gross tumor are rarely possible due to lung toxicity. 2, 3, 5, 6 A biological response modifier approach toward decreasing pulmonary toxicity would be valuable to facilitate new improvements in radiation treatment. We have demonstrated that organ-specific (lung, [12] [13] [14] [15] [16] esophagus, [17] [18] [19] [20] oral cavity, 21 bladder, 22 or intestine 23 ) introduction of the human manganese superoxide dismutase (MnSOD) transgene by plasmid/liposomes (MnSOD-PL) or viral vectors is associated with significant uptake, increased transgene mRNA and protein availability for 48-72 h after administration, and significant protection from ionizing radiation-induced acute and chronic organ injury. 24 In both pulmonary and esophageal radiation protection models, intratracheal or intraoral administration of MnSOD-PL was shown to delay the onset of organizing alveolitis/fibrosis and esophagitis in C57BL/ 6J mice, respectively, and improve overall survival in single-or multifraction radiotherapy protocols. 20, 24 For practical clinical pulmonary radioprotection during fractionated irradiation in cancer patients, the requirement for intratracheal injection with surgical exposure of the trachea and associated trauma for each injection would be contraindicated. This obstacle has also prevented studies of clinically relevant fractionation in the mouse model, and has thus far obviated design of rational preclinical studies of the effectiveness of multiple administrations of MnSOD-PL for pulmonary radioprotection. We now report a novel inhalation method for delivery of MnSOD-PL to nonanesthetized mice in fractionated radiotherapy protocols. The results demonstrate effective nebulizer inhalation delivery of the human MnSOD transgene to the lungs of C57BL/6NHsd mice. This delivery system results in an equivalent duration of expression and biochemical activity in the mouse lung with an equivalent radiation protection compared to the intratracheal injection of MnSOD-PL.
Materials and methods
Mice C57BL/6NHsd female adult mice (25-27 g) were obtained from Harlan Sprague Dawley and housed according to IACUC protocols at the University of Pittsburgh. All protocols were approved by the IACUC of the University of Pittsburgh. Veterinary care was provided by the Division of Laboratory Animal Research of the University of Pittsburgh.
Inhalation nebulizer delivery of MnSOD-PL
An Ultra-Neb 99 ultrasonic nebulizer (DeVilbiss, Somerset, PA, USA) was used to aerosolize the plasmid/ liposome complex. DNA concentrations ranging from 0 to 2500 mg were mixed with lipofectant at a ratio of 500 mg (50 ml) of plasmid DNA to 28 ml of lipofectant (a cationic lipid consisting of DOTMA and DOPE, Invitrogen, Carlsbad, CA, USA) and incubated for 30 min at room temperature. The plasmid/liposomes were diluted to 1 ml of water and placed in the ultrasonic bath of the nebulizer and delivered to mice over 5 min. In other experiments, plasmid DNA concentrations of 500 mg were aerosolized and delivered over either 0.5, 1, 2.5, 5, 7.5, or 10 min. A control plasmid/liposome complex containing alkaline phosphatase was also used. According to data from DeWilbiss, the liposomes are aerosolized into particles ranging in size from 0.5 to 3 mm. The UltraNeb 99 has a maximum aerosol output of 6.0 ml/min. A fan in the nebulizer moved the aerosolized particles down a small tube (diameter 22 mm) connected to a 50 ml conical centrifuge tube, which was cutoff at 5 mm ( Figure 1 ). The nebulizer was adjustable to deliver the total constant volume of 1.0 ml at rates varied to intervals between 30 s and 10 min. The mice were placed one at a time into the tube with the nose extending 0.5 cm from the end of the conical tube and the tube cap was placed at the posterior end of the mouse with the tail gently folded into the tube. The cap had a 2.2 cm hole cut into it with a tube extending 10 cm and connected to a hepafilter (28022 ISO-Gard Hepa Light, Hudson RCI AB, Upplands Vasby, Sweden) to keep aerosolized particles from reaching the surrounding room air. In this manner, all aerosolized plasmid/liposome particles were forced down the tube past the mouse nose for optimal effect of inhalation during respiration. For the present experiments, a plasmid transgene containing an epitope-tagged hemagglutinin MnSOD (HA-MnSOD) transgene was compared to another construct with an alkaline phosphatase (Alk) transgene.
Intratracheal injections of plasmid/liposome complexes
C57BL/6NHsd mice were injected intratracheally with plasmid/liposome complexes as previously described. 12, 13 Briefly, the mice were anesthetized with Nembutal after which the skin and muscle was cut exposing the trachea. A 28-gage needle was inserted into the trachea and 75 ml of plasmid/liposomes was injected into the lungs. The wound was then closed using wound clips.
Measurement of MnSOD biochemical activity
Mice were killed 24 h after inhalation of MnSOD-PL or alkaline phosphatase-PL (Alk-PL). The lungs were expanded in OCT, and then two of the lobes were frozen in OCT while the remaining three lobes were snap-frozen in liquid nitrogen. The lobes that had been frozen in liquid nitrogen were thawed, homogenized, and protein levels quantitated. Aliquots of 0-400 mg of protein were incubated in 20 mM PBS, 1 nM diethylenetriamine pentaacetate acid (DEPATAC), 1 U catalase, 5.6 Â 10 À8 M nitroblue tetrazolium (NBT), 0.1 mM xanthine, 0.05 mM bathocuproinedisulfonic acid (BCS), 0.13 mg/ml defatted bovine serum albumin (BSA), and 5 mM sodium cyanide for 45 min at room temperature. Xanthine oxidase (10 À2 M) was added and the change in absorbance at 560 nm as a function of time was measured. In this reaction, superoxide produced by the reaction of xanthine with xanthine oxidase is reduced by NBT, resulting in an increase in absorbance at 550 nm. In the presence of MnSOD, superoxide is converted to hydrogen peroxide, thus preventing the reduction of NBT and inhibiting the increase in absorbance. Samples containing higher levels of MnSOD result in increased inhibition of the colorimetric assay as described previously. 12 One unit of MnSOD biochemical activity is the amount of protein resulting in a 50% inhibition of the reduction of NBT by superoxide.
Immunohistochemical detection of alkaline phosphatase or HA-MnSOD transgene expression in the lungs
Mice were killed at serial times after the inhalation of the plasmid/liposome complex as described above. The lungs were expanded in OCT, frozen in OCT, and sectioned. For alkaline phosphatase expression, the sections were fixed in 5% formaldehyde for 30 min at room temperature, washed, and heated in PBS at 651C for 1 h. Sections were then cooled to room temperature and incubated in a solution containing 0.1 M Tris-HCl (pH 9.5), 0.1 M sodium chloride (NaCl), and 0.05 M magnesium chloride (MgCl 2 ). For every 10 ml of solution, we added 44 ml of NBT solution and 33 ml of BCIP solution, which was obtained from alkaline phosphatase substrate kit from Invitrogen (Carlsbad, CA, USA). To detect epitope-tag HA expression, the sections were fixed for 20 min at 41C in methanol, washed three times for 5 min in PBS, and incubated for 2 h at room temperature with of 1:100 dilution of an anti-HA mouse monoclonal antibody clone 12CA5 (Roche, Indianapolis, IN, USA). The slides were washed three times for 5 min in PBS, and then incubated for 1 h at room temperature with a 1:200 dilution of an alkaline phosphatase-conjugated goat antimouse antibody (Invitrogen, Carlsbad, CA, USA). The sections were then stained for alkaline phosphatase activity as described above. The sections were covered with gel mount (Biomeda Corp., Foster City, CA, USA), coverslipped, and observed under a light microscope. At least 10 slides were reviewed from each group of at least five mice per group.
Quantitation of level of protection from lethal irradiation-induced organizing alveolitis/fibrosis by inhalation of HA-MnSOD-PL At 24 h following inhalation of HA-MnSOD-PL or Alk-PL (1 mg plasmid DNA), the upper body of mice inhaling HA-MnSOD-PL or Alk-PL as well as that of control nontreated mice was irradiated with 20 Gy. The mice were shielded as described 12 so that only the lungs were exposed to irradiation. The mice were then followed for survival.
Statistics
A Student's t-test was used to analyze data comparing one group of mice to another group. In these experiments, we used three mice in each comparison group. A power analysis was performed to verify that statistical significance was obtained. A one-sided ANOVA test was performed to demonstrate significant differences within groups differing in inhalation times or amount of plasmid DNA inhaled. Individual inhalation times or amounts of DNA were compared to other individual groups using a Student's t-test. In order to compare the survival data for irradiated control mice or Alk-PLtreated mice with that of the mice inhaling MnSOD-PL, we used a log-rank test. In the survival experiment, we used 10 mice in each of the three groups.
Results
To demonstrate that plasmid/liposome complexes could be delivered to the lung using a nebulizer, we first measured inhalation-mediated compared to intratracheal injection 12 transgene uptake and expression in nonirradiated mice. Lung sections from mice inhaling plasmid/ liposome complexes were compared to those from mice intratracheally injected with MnSOD-PL or Alk-PL and assayed for gene expression ( Figure 2 ). The lung sections of mice that inhaled Alk-PL or MnSOD-PL showed alkaline phosphatase activity or expression of the HA protein, respectively, in 18.371.7 and 13.372.3% of cells, respectively, compared to 25.673.1 and 16.972.2% of lung cells in mice intratracheally injected with Alk-PL or MnSOD-PL, respectively. The expression resulting from inhalation of Alk-PL or HA-MnSOD-PL may be less than that for the intratracheal injection since the injections are directly into the lungs where all the plasmid/liposome complexes will be deposited. During inhalation, some of the plasmid/liposome complexes will be taken up in the nasal cavity and the upper trachea. In addition, not all of the plasmid/liposome complexes will be inhaled, as some of the plasmid/liposome complexes will pass by the mouse's nose during exhalation. Following either inhalation or intratracheal injection of HA-MnSOD-PL, 20-25% of HA-positive lung cells were found to be endothelial cells by microscopic examination. To prepare the inhalation technique for MnSOD-PL delivery to protect the lungs from fractionated irradiation-induced injury, we next optimized the weight of transgene DNA and delivery time for inhaling plasmid/liposome complexes.
Ultrasonic nebulizer inhalation delivery of MnSOD-PL results in plasmid weight dose-dependent detection of transgene product in the mouse lung Groups of C57BL/6NHsd mice were first placed individually into the inhalation device and exposed to varying concentrations ranging from 250 to 2500 mg HAMnSOD-PL in 1 ml volume over 5 min. An interval of 5 min was first chosen as an arbitrary time to quantitate the expression of MnSOD. As shown in Figure 3a , there was a dose-dependent response curve of plasmid DNA relative to gene product detected in lung over the range of 250-2500 mg plasmid using immunohistochemistry to quantitate MnSOD transgene expression by the percent of HA-positive cells in the lung. ANOVA analysis verified the dose-response curve (P ¼ 0.0006) by comparing the percent of HA-positive cells for the different amounts of DNA inhaled. This test revealed that the groups were significantly different from each other in the range of 250, 500, 1000, and 2500 mg MnSOD. A Student's t-test was used to evaluate which of the specific DNA weights were different from other DNA weights. As shown in Figure 3a and Table 1 , inhalation of increasing weights of HA-MnSOD in a constant 1 ml volume of liposomes resulted in a significant increase in the percent of cells expressing the HA-MnSOD transgene in mice injected with 500, 1000, or 2500 mg of plasmid DNA compared to 250 mg (P ¼ 0.0272, 0.0103, or o0.0001, respectively). As shown in Figure 3b and Table 1 , increasing concentrations of HA-MnSOD resulted in a significant increase in MnSOD biochemical activity compared to control mice. There was no significant difference in MnSOD biochemical activity between the groups relative to the weight of MnSOD-PL inhaled. The results establish that over a 5 min inhalation interval Lung irradiation protection by inhalation of MnSOD-PL M Carpenter et al once the optimal MnSOD level of activity was reached, further increase in plasmid DNA concentration did not further increase activity.
Optimization of inhalation time for delivery of a constant weight of MnSOD-PL to adult mice
To determine the optimal time interval of inhalation, C57BL/6NHsd mice inhaled a constant weight of 500 mg of MnSOD-PL in constant 1 ml volume with nebulizer adjusted to deliver the entire amount over 0.5, 1.0, 2.5, 5, 7.5, or 10 min. At 24 h after the procedure, the mice were killed and lungs expanded in OCT. Five lobes of the mouse lung were divided in two sections: two lobes were used to determine the percent of HA-positive cells in the lung and three lobes were used to determine MnSOD biochemical activity. The percent of cells expressing HAMnSOD was scored and found to be similar for all four time points examined. A one-sided ANOVA analysis demonstrated that the percent of HA-positive lung cells was significantly different dependent on the inhalation time over the range 0.5-1.0 min (P ¼ 0.0225). To determine which specific inhalation time was different from the control mice as well as the other inhalation times, a Student's t-test was performed comparing each inhalation time individually with the other inhalation times. Mice inhaling HA-MnSOD-PL for 0.5 min had a significantly lower percent of HA-positive lung cells than the inhalation time periods of 2.5, 5, 7.5, or 10 min (P ¼ 0.0015, 0.0187, o0.0001, or 0.010, respectively). There was no significant difference in the percent of cells positive for HA between the different time groups of 1 min or longer ( Figure 4a and Table 2 ). Increased MnSOD biochemical activity was found at 1.0, 2.5, 5, 7.5, or 10 min compared to control MnSOD activity ( Figure  4b and Table 2 ). There was no significant difference at 0.5 min compared to the control MnSOD activity ( Figure  4b and Table 2 ).
Inhalation of MnSOD-PL prolongs survival following 20 Gy irradiation to the lungs
We next evaluated the effectiveness of inhalation of MnSOD-PL at preventing irradiation-induced lung damage. C57BL/6NHsd mice inhaled 1 mg of plasmid DNA in 1 ml liposomes (MnSOD-PL or Alk-PL), over a constant 5 min time interval. The lungs of mice in each transgene group and those of control nontreated mice were then irradiated 24 h later with 20 Gy and the mice were followed for survival. The control irradiated mice as well as Alk-PL inhalation-treated and then irradiated mice had a similar survival following 20 Gy irradiation ( Figure 5 ). In contrast, mice that inhaled MnSOD-PL had a significantly increased survival compared to the control irradiated or Alk-PL-treated mice ( Figure 5 ) (P ¼ 0.0271 or 0.0131, respectively). . There was also a significant increase in MnSOD activity in mice that received MnSOD-PL twice weekly compared to Alk-PL-injected mice (P ¼ 0.003). Daily inhalations of MnSOD-PL also resulted in a significant increase compared to mice inhaling Alk-PL (P ¼ 0.0244). These results establish that a fractionated administration of MnSOD-PL during a fractionated irradiation schedule is feasible and results in stably increased and effective transfer of transgene MnSOD product and activity.
Discussion
Organ-and tissue-specific radiation protection therapies have become a subject of intense investigation in recent years. [9] [10] [11] [12] [25] [26] [27] [28] [29] [30] [31] With the availability of sophisticated computer-controlled modification systems for clinical radiotherapy dose distribution by modern linear accelerators including intensity-modulated radiation therapy, 1,2,7 many physical barriers to dose optimization in complex tumor volumes have been overcome. Unfortunately, effective high dose delivery to complex tumor volumes in the thoracic cavity, which has been developed for patients with lung cancer, esophagus cancer, and other thoracic malignancies, has necessitated often large lung transit volumes and associated toxicity. 2, 3 The most effective radiosensitizing chemotherapy agents including Taxol and derivatives, Carboplatinum and derivatives, and Gemcitabine also produce increases in irradiation-induced normal tissue toxicity. 2, 8 Pulmonary toxicity remains a major dose-limiting event, which prevents effective dose escalation for Dose-dependent increase in MnSOD transgene product delivery and activity following inhalation of MnSOD-PL. C57BL/6NHsd mice in the nebulizer apparatus inhaled MnSOD-PL with concentrations of plasmid DNA of 0, 250, 500, 1000, or 2500 mg and were then killed 24 h later. The lungs were expanded in OCT, excised, and divided into two portions: one portion was frozen in OCT and sectioned for immunohistochemistry for expression of HA-MnSOD and the remaining portion was frozen in liquid nitrogen to determine MnSOD biochemical activity. There was a significant increase in the percent of lung cells positive for HAMnSOD when comparing inhalation of 500, 1000, or 2500 mg of plasmid DNA to the 250 mg group (Pp0.0272) (a). There was a significant increase in MnSOD biochemical activity for all the groups inhaling MnSOD-PL compared to the control mice (Pp0.0241) (b) (n ¼ 3 mice per group). Mice inhaled varying concentrations of HA-MnSOD-PL plasmid DNA ranging from 250 to 2500 mg in a 1 ml volume over 5 min and were killed 24 h later. The lungs were expanded and separated into two groups for measurement of the percent of cells positive for expression of HA-MnSOD or MnSOD biochemical activity. There was a significant increase in expression of HA-MnSOD in all mice inhaling MnSOD-PL (Po0.0001). A one-way ANOVA test demonstrated that there were significant differences within the groups receiving each different weights of DNA (250, 500, 1000, or 2500 mg) (P ¼ 0.0006). Individual t-tests comparing the percent of cells with positive HA expression in the 500, 1000, or 2500 mg groups against the 250 mg HA-MnSOD-PL group showed a significant increase in HA expression following injections of 500, 1000, or 2500 mg of plasmid DNA (*P-value shown) (three mice per group).
Lung irradiation protection by inhalation of MnSOD-PL M Carpenter et al inoperable lung and esophagus cancer patients. 5, 6 Furthermore, patients suffering from local recurrence after conventional radiotherapy programs for lung and esophagus cancer often cannot be treated because of unacceptable lung toxicity. 5, 6 A method by which to protect the normal lung from ionizing irradiation damage while not providing tumor radiation protection would be a valuable resource for modern radiotherapy. Such a method of lung radiation protection might also be applicable to environmental radiation protection for radiation safety workers, nuclear reactor clean-up personnel, and emergency response personnel working in an area of unanticipated continuous low level of ionizing irradiation contamination. 25 There have been many approaches attempted for designing new modalities for radiation protection.
Pharmacologic interventions and biologic response modifiers have recently been focused on pulmonary radiation protection. Intravenous or systemic delivery of compounds such as WR2721 (Amifostine), [9] [10] [11] [26] [27] [28] [29] 32 colony stimulating factors, 31 or other antioxidant molecules 30, 33, 34 has the potential problem of distribution to tumor vasculature within the target volume. 27, 29 Simultaneous tumor and normal tissue radiation protection would not alter the therapeutic ratio or shift to a desirable effect of normal tissue radiation protection. Figure 5 Preirradiation inhalation of MnSOD-PL increases survival following 20 Gy pulmonary irradiation. C57BL/6NHsd mice inhaled 1 mg of plasmid DNA in 1.0 ml for Alk-PL or HA-MnSOD-PL over a time frame of 5 min. After 24 h, the pulmonary cavity of mice inhaling the plasmid/liposome preps as well as that of control mice was irradiated with 20 Gy and the mice were followed for survival. Mice inhaling the alkaline phosphatase and then irradiated had the same survival as mice receiving irradiation only. In contrast, mice inhaling MnSOD-PL 24 h before irradiation had increased survival compared to the control or Alk-PL group (P ¼ 0.0271 or 0.0131, respectively) (n ¼ 10 mice per group).
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Inhalation models for lung radiation protection have followed therapeutic success in other models of inhalation drug delivery. Inhalation delivery of Pentamadine for prophylaxis in treatment of pneuomocystis carinii and inhalation delivery of other antibiotic, antifungal, and immunostimulatory agents has gained some success in clinical trials. 35 The use of gene therapy vectors including adenovirus, adeno-associated virus, and plasmid/liposomes has been evaluated in inhalation models for transgene delivery in several disease categories. [36] [37] [38] [39] [40] [41] [42] [43] The availability of ultrasonic nebulizer devices, and successful development of inhalant drug delivery systems for asthma, obstructive pulmonary disease, and pulmonary allergic reactions have provided significant resources with respect to blood dose delivery to primary, secondary, and tertiary bronchi. [41] [42] [43] A technique by which to transiently elevate pulmonary levels of a transgene protein would not be particularly desirable for therapy of patients with cystic fibrosis treatment; however, such transient and controllable expression could be potentially therapeutic for conditions requiring transient availability of pulmonary transgene proteins such as prior to an anticipated pulmonary toxic inhalation injury, or injury from a toxic agent with potential pulmonary negative sequelae, including intracavitary irradiation.
In this series of experiments, we have used an ultrasonic nebulizer instead of a jet nebulizer. Although jet nebulization can produce smaller particle size, the prolonged treatment time compared to ultrasonic nebulization may render the jet nebulization disadvantageous. The use of an ultrasonic nebulizer avoids the problems of increasing drug concentration in the drug reservoir compared to jet nebulizers. The theoretical problem of increased temperature in the drug reservoir during ultrasonic nebulization was not a practical problem during these experiments. 44 Our laboratory has recently reported the effectiveness of intratracheal administration of transgene for the antioxidant protein MnSOD delivered by plasmid/liposomes, or adenovirus, in a mouse model. 12, 13 A pulmonary inflammatory response to adenovirus and a relative equal effectiveness of noninflammatory liposome delivery were observed. This led us to focus on the plasmid/ liposome delivery system in subsequent studies. In studies of intratracheal injection, transgene MnSOD mRNA was detectably elevated for 48-72 h, 12 transgene protein was elevated for 48 h, 12, 45, 46 and persistence of epitope-tagged MnSOD protein was preferentially expressed in endothelial cells for up to 72 h, 45 while clearance of transgene protein from bronchoalveolar macrophages and alveolar type II cells was detected at 48 h. 45 Heterozygous recombinant negative MnSOD knockout mice were more sensitive to pulmonary radiation injury compared to normal littermates, and relative restoration of radioresistance was provided by MnSOD-PL intratracheal transgene delivery. 15 Intratracheal injection of MnSOD-PL had maximal MnSOD biochemical activity at 100 mg of MnSOD-PL. 45 Injections of 250-1000 mg of MnSOD-PL resulted in no further increases in MnSOD biochemical activity. This result is in agreement with our current studies where inhalation of 250 mg or higher resulted in similar levels of MnSOD biochemical activity. McCord and coworkers [47] [48] [49] have reported that expression of high levels of MnSOD is not beneficial or protective. It is possible that a protective mechanism in the lung may regulate levels of MnSOD.
A mitochondrial subcellular site-specific mechanism for MnSOD radiation protection has been demonstrated in both cell lines in culture, and in the mouse esophagus. 50, 51 In contrast, there was no detectable protective effect of Cu/ZnSOD, which was cytoplasmic expressed in vitro, or in organ-specific esophagus radiation protection in vivo. 51 However, by using a construct of the Cu/ZnSOD transgene to which was attached the mitochondrial localization signal of MnSOD, an effective transgene protein for radioprotection was demonstrated. 51 MnSOD-PL administration prior to irradiation of lung, 12 oral cavity, 21 esophagus, 17 bladder, 22 and intestine 23 has Lung irradiation protection by inhalation of MnSOD-PL M Carpenter et al been shown to provide radioprotection in each organ's target volume. In two model systems (lung and oral cavity), orthotopic tumors were not detectably protected from irradiation killing under conditions of normal tissue radiation protection. 21, 52 Transient overexpression of MnSOD in tumor cell lines in vitro has been demonstrated to increase radiosensitivity, confirming studies by Oberley and co-workers 53, 54 and documenting the intrinsic inability of squamous and adenocarcinoma cell lines to neutralize effectively hydrogen peroxide produced by dismutation of superoxide. 54 For effective translation of MnSOD-PL pulmonary radiation protection to clinical radiotherapy, its adaptation for use in fractionated radiotherapy using clinically relevant doses in the range of 180-210 cGy/day was felt to be essential. Furthermore, repeat transgene treatments would require demonstration of safety during a 6-to 7-week treatment course (28-38 treatments) for patients with non-small cell lung carcinoma of the lung or esophagus cancer. These two disease categories include large numbers of patients who present with unresectable cancers and in whom radiotherapy dose-escalation protocols must be developed. We have demonstrated that inhalation of MnSOD-PL twice weekly or on a daily basis is effective in expression of MnSOD. The results from daily inhalation ( Figure 6 ) are comparable to that of a single inhalation of MnSOD-PL (Figure 4) for percent of cells positive for HA-MnSOD and MnSOD biochemical activity. This is in agreement also in that there seems to be a maximal expression of MnSOD level, which cannot be exceeded by inhaling higher doses of MnSOD-PL ( Figure 3) .
While intraoral or intraesophageal administration of MnSOD-PL has been demonstrated to be effective in murine models, due in part to the ease of administration, 21 translation of this technique to pulmonary protection clearly requires a safe inhalation delivery method without the trauma of intratracheal injection. Previous studies demonstrated relative ineffectiveness of administration of MnSOD protein for esophagus radiation protection, presumed attributable to the relative lack of concentration of protein in cellular mitochondria. 20 Studies with a tet-inducible MnSOD, mitochondriallocalized MnSOD variant, and a MnSOD small molecule mimic are in progress, but to date, only transgene MnSOD delivery has been shown to be an effective radioprotector in our system.
In the present studies, we have demonstrated the effectiveness of an ultrasonic nebulizer method for delivery of HA-MnSOD-PL in lungs of mice during protocols of single and fractionated radiotherapy. MnSOD-plasmid dose weight-response curves, and time of administration-response curves demonstrated effective delivery of epitope-tagged (hemagglutinin) to peripheral lung of C57BL/6NHsd mice utilizing doses of plasmid as low as 250 mg and inhalation times as low as 1.0 min. Optimal transgene product delivery was detected utilizing 500 mg in a 5-7 min inhalation time. The irradiation fractionation experiments demonstrated effective continuous HA-MnSOD uptake in the lung at varying time points during multiple administration protocols, indicating that irradiation treatment between gene therapy applications did not detectably inhibit uptake or expression of subsequent transgene product deliveries. Of particular interest, inhalation delivery of MnSOD-PL was as effective as intratracheal injection with respect to prolongation of survival and reduction of the severity of organizing alveolitis/fibrosis in single fraction experiments.
The present data provide support for translation of MnSOD-PL gene therapy to the clinic for radiation protection during fractionated chemoradiotherapy protocols in patients receiving radiotherapy for lung or esophagus cancer. Further studies will be required to optimize present treatment schedules for patients in clinical protocols.
